Benzinga | Jul 29, 2020 05:32PM EDT

Recap: Alimera Sciences Q2 Earnings

Shares of Alimera Sciences (NASDAQ:ALIM) decreased 1.5% after the company reported Q2 results.

Quarterly Results

Earnings per share fell 628.57% year over year to ($0.51), which beat the estimate of ($1.44).

Revenue of $10,038,000 declined by 7.53% year over year, which beat the estimate of $6,940,000.

Outlook

Alimera Sciences hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Price Action

52-week high: $9.98

52-week low: $0.00

Price action over last quarter: Up 12.13%

Company Overview

Alimera Sciences Inc is a pharmaceutical company. It specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. The product portfolio of the company includes ILUVIEN, which is developed to treat diabetic macular edema. In addition, to the activities related to the development of ILUVIEN, the group is also researching the safety and effectiveness of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors. Geographically it operates through the region of US and also it has its presence in the international market.